Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 17/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.39 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6717602 | 0.80 | SSTR3 (0.65) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL6717600 | 0.80 | SSTR3 (0.65) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL6716256 | 0.77 | SSTR3 (0.69) | SSTR3KCNH2MEN1KMT2AKDM4E | |
| SCHEMBL6716252 | 0.77 | SSTR3 (0.69) | SSTR3KCNH2MEN1KMT2AKDM4E | |
| SCHEMBL13244879 | 0.74 | KDM4E (0.49) | SSTR3KCNH2KDM4EALDH1A1 | |
| SCHEMBL13244716 | 0.74 | SSTR3 (0.69) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL3010196 | 0.73 | SSTR3 (0.50) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL1244095 | 0.72 | SSTR3 (0.70) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL12890523 | 0.72 | SSTR3 (0.70) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL3010300 | 0.72 | SSTR3 (0.46) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377578-B1 | BETA-CARBOLINE DERIVATIVES AND ITS PHARMACEUTICAL USE AGAINST DEPRESSION AND ANXIETY | NOVARTIS AG (CH) | 2011-07-20 | — | — | EP | claimed |
| US-6861430-B2 | β-carboline derivatives and its pharmaceutical use against depression and anxiety | NOVARTIS AG (CH) | 2005-03-01 | — | — | US | claimed |
| US-20040132735-A1 | Beta-carboline derivatives and its pharmaceutical use aginst depression and anxiety | NOVARTIS AG (CH) | 2004-07-08 | — | — | US | claimed |
| EP-1377578-A1 | BETA-CARBOLINE DERIVATIVES AND ITS PHARMACEUTICAL USE AGAINST DEPRESSION AND ANXIETY | Novartis AG (CH) | 2004-01-07 | — | — | EP | claimed |
| WO-2002081471-A1 | BETA-CARBOLINE DERIVATIVES AND ITS PHARMACEUTICAL USE AGAINST DEPRESSION AND ANXIETY | NOVARTIS AG (CH) | 2002-10-17 | — | — | WO | claimed |
| US-7879859-B2 | increasing insulin secretion via somatostatin subtype 3 receptor (SST3) as target; knocking down expression of SST3 selective antagonist | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090131451-A1 | Diagnosis and treatment of type 2 diabetes and other disorders | MERCK SHARP & DOHME CORP. | 2009-05-21 | — | — | US | disclosed |
| US-6861430-B2 | β-carboline derivatives and its pharmaceutical use against depression and anxiety | NOVARTIS AG (CH) | 2005-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132735-A1 | Beta-carboline derivatives and its pharmaceutical use aginst depression and anxiety | ADRB1, ADRB2, ADRA1B | SSTR3 1415/4885KCNH2 727/4885CACNA1F 404/4885 |
| US-20090131451-A1 | Diagnosis and treatment of type 2 diabetes and other disorders | SSTR3, SSTR2, SSTR4 | SSTR3 1/4885KCNH2 2449/4885CACNA1F 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.